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Abstract
Human motor neurons derived from embryonic and induced pluripotent stem cells (hESCs and hiPSCs) are a potentially
important tool for studying motor neuron survival and pathological cell death. However, their basic survival requirements
remain poorly characterized. Here, we sought to optimize a robust survival assay and characterize their response to different
neurotrophic factors. First, to increase motor neuron yield, we screened a small-molecule collection and found that the Rho-
associated kinase (ROCK) inhibitor Y-27632 enhances motor neuron progenitor proliferation up to 4-fold in hESC and hiPSC
cultures. Next, we FACS-purified motor neurons expressing the Hb9::GFP reporter from Y-27632-amplified embryoid bodies
and cultured them in the presence of mitotic inhibitors to eliminate dividing progenitors. Survival of these purified motor
neurons in the absence of any other cell type was strongly dependent on neurotrophic support. GDNF, BDNF and CNTF all
showed potent survival effects (EC50 1–2 pM). The number of surviving motor neurons was further enhanced in the
presence of forskolin and IBMX, agents that increase endogenous cAMP levels. As a demonstration of the ability of the assay
to detect novel neurotrophic agents, Y-27632 itself was found to support human motor neuron survival. Thus, purified
human stem cell-derived motor neurons show survival requirements similar to those of primary rodent motor neurons and
can be used for rigorous cell-based screening.
Citation: Lamas NJ, Johnson-Kerner B, Roybon L, Kim YA, Garcia-Diaz A, et al. (2014) Neurotrophic Requirements of Human Motor Neurons Defined Using
Amplified and Purified Stem Cell-Derived Cultures. PLoS ONE 9(10): e110324. doi:10.1371/journal.pone.0110324
Editor: Jan Pruszak, University of Freiburg, Germany
Received April 22, 2014; Accepted September 18, 2014; Published October 22, 2014
Copyright:  2014 Lamas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: This work was funded by Project A.L.S., P2ALS and NYSTEM grant number CO24415. The work of N.J.L. was supported by the Portuguese Foundation
for Science and Technology SFRH/BD/33421/2008 and the Luso-American Development Foundation. B.J.-K. was supported by the National Institute of
Neurological Disorders and Stroke (NINDS). L.R. was supported by the Swedish Brain Foundation/Hja¨rnfonden. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: ch2331@columbia.edu
¤ Current address: Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Ska˚ne, Sweden
Introduction
In vitro differentiation of specific cell types from human
pluripotent stem cells (hPSCs) allows for molecular and functional
analysis of cells that are otherwise inaccessible. This holds special
promise in neurodegenerative diseases such as amyotrophic lateral
sclerosis (ALS), where ethical and technical constraints prevent
access to human spinal motor neurons [1]. Using protocols based
on normal developmental pathways, it has proven possible to
generate spinal motor neurons from both mouse and human
embryonic stem cells (ESCs) [2–6]. These are an important source
of new mechanistic insights into the developmental requirements
of wildtype motor neurons in both species. Moreover, successful
specification of motor neurons from human induced pluripotent
stem cells (hiPSCs) has opened novel avenues for mechanistic
analysis of neuronal cell death and drug testing in motor neuron
disease models [1,4–8]. Yet our knowledge of the survival
requirements of human motor neurons remains limited.
Cultured motor neurons from rodent embryos served as the
basis for identification of the neurotrophic factors responsible for
keeping motor neurons alive during development [9–11] and the
same factors significantly retard motor neuron death in animal
models of ALS [12]. In parallel, motor neurons cultured from
mouse models of ALS shed light on the mechanisms underlying
neurodegeneration [13]. All these discoveries required the
purification of motor neurons from the complex environment of
the spinal cord. This approach allowed for identification of factors
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that act directly on motor neurons, significantly facilitated direct
quantification of motor neuron survival, and opened the door to
biochemical studies that would not have been possible in mixed
cultures. Although this might be considered a reductionist
approach, conclusions about both survival factors and cell death
mechanisms were subsequently validated in vivo [14–21],
demonstrating that the advantages of motor neuron purification
outweigh concerns about the artificial nature of the assay. It is
therefore important to extend such approaches to human motor
neurons. However, standard protocols for hPSC differentiation
generate mixed populations of spinal neurons of which motor
neurons constitute a minority, and to date survival of purified
motor neurons has necessitated generally co-culture with other cell
types [22–25]. There is consequently a need for a robust survival
assay based on purified human motor neurons.
Another challenge is that absolute numbers of motor neurons
generated from hESC/hiPSCs by standard procedures are
relatively low. During embryonic development in rodents, motor
neurons are produced from a short-lived pool of committed
ventral spinal progenitors expressing OLIG2, which are rapidly
exhausted or converted to oligodendroglial progenitors [26,27].
However, in contrast to mouse motor neurons, which are
produced during a brief period between embryonic days 9 and
12, the period of human motor neuron generation spans
approximately twenty days [28,29]. This raises the possibility that
agents that enhance proliferation of motor neuron progenitors
might be used to increase the yield of human motor neurons in
culture.
Here we have developed techniques that allow us both to
amplify stem cell-derived motor neurons and to perform survival
assays in the absence of other cell types. We first report that there
is indeed significant ongoing motor neuron generation in cultures
of differentiated hESCs. To exploit this so as to increase yield, we
therefore screened for compounds that increase the number of
motor neurons when applied over this period. We report that the
ROCK inhibitor Y-27632 stimulates the proliferation of OLIG2-
expressing progenitors, and increases the yield of motor neurons
up to four-fold. Using amplified motor neurons from the
Hb9::GFP hESC line, we next defined conditions for a robust
survival assay using FACS-sorted motor neurons, and used it to
demonstrate potent activity for three known neurotrophic factors
as well as Y-27632 itself. These approaches should be of general
interest for the preparation of human motor neurons on a large
scale and for functional and biochemical studies of molecular
processes controlling motor neuron genesis, survival and degen-
eration.
Results
Ongoing motor neuron generation in cultures of
differentiated hESCs
To determine whether hESCs differentiated in vitro to a mixed
spinal cord identity exhibit prolonged motor neurogenesis as in the
fetal human spinal cord, we first examined changes in numbers of
hESC-derived motor neurons (hESC-MNs) in mixed spinal
cultures over a 15-day period using an hESC reporter line that
expresses green fluorescent protein (GFP) under the control of the
motor neuron-specific murine homeobox gene 9 (Hb9) promoter
[23]. We and others previously showed using a range of other
markers and functional assays that GFP-positive neurons gener-
ated from this line possess many properties of postmitotic motor
neurons [6,23,30]. Motor neurons were differentiated from hESCs
using a standard protocol involving exposure of embryoid bodies
(EBs) to retinoic acid (RA) and recombinant sonic hedgehog
protein (SHH) (see Methods) [4,6]. After 31 days, EBs were
dissociated and cryopreserved to allow multiple experiments to be
performed on identical aliquots; however, similar data were
obtained using fresh, unfrozen cells (not shown). Cell suspensions
were thawed and plated in 96-well plates and automated counts of
live motor neurons, defined as GFP+ neurons with significant
neurite outgrowth (SNO, total neurite length .75 mm), were
performed (Figures 1A and 1B) [31–33]. In standard culture
medium without neurotrophic support motor neuron numbers
decreased over the first 7 days, reaching a plateau that was
maintained until day 31+13 (Figure 1C and 1D). This did not
reflect a loss of reporter expression since a similar decrease was
seen when motor neurons were identified by staining for
endogenous HB9 (not shown). In contrast, when the medium
was supplemented with four neurotrophic factors [NTFs; brain-
derived neurotrophic factor (BDNF), ciliary neurotrophic factor
(CNTF), glial cell line-derived neurotrophic factor (GDNF) and
insulin-like growth factor 1 (IGF-1) at 10 ng/mL] in addition to
the cAMP-elevating compounds forskolin (F; 10 mM) and iso-
butylmethylxanthine (I; 100 mM), after an initial decrease in motor
neuron numbers by day 31+7, there was a subsequent increase in
the number of hESC-MNs, which reached nearly starting levels by
day 31+13 (Figure 1C and 1D).
This late increase in human motor neuron numbers could
potentially be explained by ongoing genesis of motor neurons. To
assess overall generation of new-born motor neurons we cultured
cells with or without NTFs in the continuous presence of the
mitotic label 5’-bromo-2’deoxyuridine (BrdU, 2 mM) and counted
GFP-positive cells that had incorporated BrdU (Figure 1E). After
15 days, ,60% of all Hb9::GFP cells were positive for BrdU in
both conditions (Figures 1F and 1G), but cultures supplemented
with NTFs contained 4-fold higher absolute numbers of new-born
hESC-MNs (Figure 1G, p,0.05). Together, these results demon-
strate that human motor neurons are generated over extended
periods of culture and that the yield of motor neurons can be
increased by treatment with neurotrophic factors.
Screening for small molecules able to increase the yield
of human motor neurons
Neurotrophic factors are costly culture supplements and have
pleiotropic effects on neural development [16,34,35]. To exploit
the high rate of neurogenesis in hESC-MN cultures in a more
targeted manner to increase motor neuron yields, we sought to
identify available reagents with similar activity. We therefore
performed a small-scale screen of 160 bioactive compounds
selected from a collection of drug-like chemicals and examined
their effect on total motor neuron numbers. We reasoned that the
assay might capture two types of compounds, those that increase
motor neuron survival and/or others that increase motor
neurogenesis. Both types of compounds would be of interest as
they could be applied to increase the overall yields of motor
neurons derived from hESCs.
Compounds (10 mM in quadruplicate wells) were added on the
day of seeding and motor neurons were counted at day 31+13, the
time point at which the greatest differences in human motor
neuron numbers between control and NTF-supplemented cultures
were observed (Figure 1C, p,0.001). Most compounds showed no
effect, and a significant number resulted in lower motor neuron
numbers than the negative control condition (Figure 2A). In
contrast, two compounds increased motor neuron numbers by.
1.4 fold compared to basal conditions (Figure 2A). The most
significant increase (1.9-fold) was induced by the Rho kinase
(ROCK) inhibitor Y-27632 (Figure 2A, Y-27632 vs. No NTFs,
p,0.05).
Survival Factors for Human Motor Neurons
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e110324
Figure 1. Ongoing birth of motor neurons in hESC-derived cultures is stimulated by neurotrophic factors. (A) Live fluorescent human
motor neurons derived from the Hb9::GFP reporter line at day 31+13 after growth with a cocktail of neurotrophic factors (NTFs). (B) Automated
quantification of fluorescent cells with significant neurite outgrowth (SNO) using the Neurite Outgrowth module of MetaMorph software; cells
counted are identified with a red overlay. Motor neurons were considered to have significant neurite outgrowth when their overall neurite length
exceeded 75 mm (scale bar). (C) Representative image of immunostained Hb9::GFP hESC-motor neuron cultures at day 31+13 after growth with a
cocktail of neurotrophic factors (NTFs). Scale bar = 50 mM. (D) Number of cells with significant neurite outgrowth (SNO) when grown with (red bars) or
without (blue bars) neurotrophic factors, expressed as a percentage of numbers at day 31+1. The increase in motor neuron numbers after day 31+7 in
NTF-supplemented cultures suggests ongoing neurogenesis. Surviving fluorescent GFP-positive motor neurons with SNO shown as mean 6 s.e.m.,
n.5 (t-test, ***p,0.001, *p,0.05). (E) BrdU-positive Hb9::GFP-positive motor neurons (arrows) at day 31+15 confirming the presence of newborn
human motor neurons in culture. Scale bar = 50 mM. (F) The percentage of Hb9::GFP-positive motor neurons that were BrdU-positive at day 31+15 is
not changed by NTFs but (G) total numbers of BrdU-positive motor neurons are increased with NTFs. Bars indicate mean 6 s.e.m., n= 3 (t-test, *p,
0.05; n.s. = not significant).
doi:10.1371/journal.pone.0110324.g001
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The EC50 for Y-27632 at day 31+13 was 1.9 mM with a
maximum effect of ,5-fold (Figure 2B; p,0.05), even greater
than that of neurotrophic factors (Figures 2A and 2C; Y-27632 vs.
NTFs + F + I, p,0.05). To optimize the time window for the
effects of Y-27632, we next studied the kinetics of human motor
neuron generation with or without Y-27632 at its optimal
concentration (10 mM). We focused on its effects when added
post-dissociation at day 31. Maximum numbers of GFP-positive
neurons, representing a ,5-fold increase in motor neuron
numbers over basal levels (Figure 2D, p,0.05) were reached at
day 31+9, which was therefore adopted as the standard time point
for all subsequent experiments.
To exclude the possibility that Y-27632 might have affected the
fidelity of HB9 reporter expression, we checked day 31+9 cultures
Figure 2. The ROCK inhibitor Y-27632 increases humanmotor neuron numbers in hESC-derived motor neuron cultures. (A) Screening
of 160 compounds for their potential to increase the number of human motor neurons in hESC cultures at day 31+13. Compounds were tested in
quadruplicate at a single concentration (10 mM). Values are plotted as mean fold difference in motor neuron numbers relative to the negative control
condition (No NTFs). The Rho-kinase (ROCK) inhibitor Y-27632 was the compound showing the highest capacity to increase the number of human
motor neurons. (B) Y-27632 increases the number of fluorescent hESC-motor neurons in mixed cultures in a dose-dependent manner. Cells were
cultured in the absence of neurotrophic factors and in the presence of increasing concentrations of Y-27632. Values shown as mean 6 s.e.m., n= 4.
(C) Representative images of hESC-motor neuron cultures at day 31+13 grown under neurotrophic factor deprivation (No NTFs), neurotrophic factor
supplementation (NTFs + F + I) and Y-27632 (10 mM). Scale bar = 25 mM. (D) Time-dependent increase in the number of motor neurons in the
presence (green) but not absence (blue) of Y-27632 (10 mM), with a peak effect at day 31+9. Values shown as mean 6 s.e.m., n.5 (t-test, *p,0.05;
**p,0.01). (E) Y-27632 also increases the total number of cells in culture. Mean 6 s.e.m., n= 3. (F) Hb9::GFP-positive neurons continue to express
motor neuron markers HB9 and ISL1 after treatment with Y-27632 for 9 days. Scale bar = 50 mM. (G) Supplementation of cultures with Y-27632 (red
line) leads to increased numbers of human motor neurons expressing endogenous ISL1 at day 31+9. Mean 6 s.e.m., n= 3 (**p,0.01).
doi:10.1371/journal.pone.0110324.g002
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using direct immunostaining for the motor neuron markers ISL1
and HB9; both showed a high degree of overlap with the GFP
reporter (Figure 2F). Moreover, Y-27632 induced a nearly 4-fold
increase in absolute numbers of hESC-MNs expressing endoge-
nous ISL1 (Figure 2G, p,0.05). Furthermore, to exclude the
possibility that the class of motor neurons generated was altered
with respect to standard differentiation protocols, we quantified
the fraction of GFP-positive neurons expressing FoxP1, a marker
for limb-innervating motor neurons, or Lhx3, a marker of medial
motor neurons [30,36,37]. Comparable numbers of each class
were generated and the ratio was not significantly affected by
amplification with Y-27632 (p.0.05; not shown). One potential
risk of this amplification procedure was that Y-27632 might dilute
out motor neurons by stimulating the generation of other cell
types. However, this did not appear to negatively affect the
outcome: across the many different batches of hES-MNs analyzed
in this study, the final abundance of motor neurons ranged from
5% to 45% of total cells, making it important that all treatment
groups be compared to controls from the same batch. Although we
did not exclude the batches with lower abundance, the value of
45% motor neurons is among the highest reported, demonstrating
that expansion did not lead to excessive motor neuron depletion.
Thus using a small-scale drug testing approach we were able to
identify a compound, Y-27632, which can significantly increase
motor neuron numbers in differentiated hESC cultures.
Y-27632 enhances proliferation of motor neuron
progenitors in both hESC- and hiPSC-derived cultures
To better understand the level at which Y-27632 exerts its
effect, we next examined the expansion of motor neuron
progenitors (pMNs), using OLIG2 as a marker [26]. Treatment
with Y-27632 increased the number of OLIG2-positive cells,3.6-
fold compared to controls by day 31+9 (Figures 3A and 3B, p,
0.05) comparable to the ,3.3-fold increase in DAPI-stained cells
over controls over the same period [Figure 2E, p.0.05; Ratio
DAPI/OLIG2 = 6.8:1 (CONTROL) vs. 6.2:1 (Y-27632)]. Appli-
cation of BrdU from day 31 to day 31+9 led to nuclear labeling of
86% of OLIG2-positive cells, indicating that they are actively
proliferating progenitors (Figures 3C and 3D). Accordingly, 74%
of GFP-positive motor neurons on day 31+9 were BrdU-positive,
indicating that they were born during the period of Y-27632
treatment (Figures 3E and 3F). Similar percentages were observed
using fresh, unfrozen motor neuron preparations (not shown).
Therefore Y-27632 non-selectively enhances cell proliferation in
hESC-derived cultures, resulting in a ,3.5-fold increase in the
number of motor neuron progenitors that is likely to contribute
significantly to the observed increase in postmitotic hESC-MNs.
To determine whether Y-27632 was a generally effective
treatment for pluripotent stem cell lines, we performed similar
experiments using an additional hESC line, RUES1; and a hiPSC
line, 18c, derived from a healthy control subject [6]. Total
numbers of DAPI-stained cells and OLIG2-positive progenitors
were quantified as above after 31+9 days. Significant increases in
both DAPI-positive and OLIG2-positive cells were observed
following Y-27632 treatment using hiPSC 18c (Figures 3G and
3H, p,0.05) and for DAPI using RUES1 (Figure 3G). To detect
motor neurons in the absence of a reporter we performed
immunostaining for HB9, to label motor neurons, and b-III
tubulin, to label all neurons (Figures 3I and 3J). Automated image
analysis of such cultures revealed a 2- to 4-fold increase in motor
neuron numbers (Figure 3I, p,0.05). Y-27632 is therefore a useful
tool for both hESCs and clinically relevant hiPSC lines.
Design of a robust survival assay for purified human
motor neurons
Our overall goal was to study the trophic requirements of
human motor neurons. Bulk day 31 cultures were therefore
dissociated and grown in the presence of Y-27632 for 3 days or 9
days before FACS analysis, leading to a ,2-fold increase in the
total yield of motor neurons after 3 days (Figure 4A; p,0.01) and
a nearly 4-fold increase after 9 days (Figure 4B; p,0.01). For all
subsequent experiments, expanded human motor neurons from
the day 31+3 time point were used.
Given the ongoing neurogenesis in mixed cultures, it was first
necessary to find conditions in which expanded postmitotic
neurons could be studied in isolation. Direct treatment of mixed
cultures with mitotic inhibitors did not produce satisfactory results:
cytosine arabinoside (AraC) proved toxic for human motor
neurons, while even the less toxic uridine/fluorodeoxyuridine
(U/FdU) led to clumping of neurons on remaining islands of non-
neuronal cells (not shown). Motor neurons were therefore FACS-
sorted (Figure 4C) and seeded on polyornithine/laminin-coated
coverslips in medium containing a cocktail of NTFs plus the c-
AMP elevating compounds forskolin and IBMX. Using FACS
conditions involving a slow sorting rate and a wide nozzle, the
seeded motor neurons rapidly developed robust neurite outgrowth
(Figure 4D). To estimate their purity, we performed immuno-
staining using a combination of antibodies to HB9 and ISL1
(‘‘pan-MN’’) [30]. At day 31+3+1 (differentiation + expansion +
days post-FACS),.95% of the neurons were Hb9::GFP-positive,
and reporter expression showed strong overlap with HB9/ISL1
staining (Figure 4D). Despite this high degree of enrichment,
colonies of proliferating progenitors were occasionally observed
(Figure 4E); sorted motor neurons were therefore cultured in the
presence of the antimitotic drug U/FdU (Figure 4E). The new
protocol therefore provides a robust and abundant source of
highly purified hESC-MNs.
To develop a survival assay based on neurotrophic factor
deprivation [31,38,39], FACS-sorted motor neurons were seeded
in 96-well plates and stained using the vital dye calcein-AM. This
had the advantage that it stained cell bodies and neurites more
intensely than live imaging of GFP, which was no longer required
to identify motor neurons. Numbers of surviving hESC-MNs were
counted in whole culture wells in an automated manner using
MetaMorph (Figure 5A). We first asked whether the survival of
purified motor neurons was dependent on trophic support in these
conditions. At day 31+3+7, motor neuron survival was enhanced
,2.5-fold by a cocktail of NTFs (BDNF, CNTF, GDNF, IGF-1,
each at 10 ng/ml) with F (10 mM) plus IBMX (100 mM)
(Figure 5B), similar to published results using cultures of primary
rodent motor neurons [39–41]. We tested forskolin and IBMX
alone and found that they showed only slight innate neurotrophic
activity (not shown).
This provided an opportunity to better characterize the effects
of known neurotrophic factors on hESC-MNs. Doses of GDNF,
BDNF, CNTF and IGF-1 ranging from 2 pg/mL to 10 ng/mL
were first tested alone for their effects on survival at day 31+3+7
(Figure 5D to 5G). Except for IGF-1 (not shown), which showed
no survival promoting effect alone, each neurotrophic factor
provided significant support for human motor neuron survival
with EC50 values as follows: 2 pM for BDNF, 2 pM for GDNF and
1 pM for CNTF. These are slightly higher than the most potent
EC50 values reported for the same factors on primary rodent
motor neurons (BDNF, EC50 = 1 pM [38]; GDNF, EC50 = 0.2 pM
[31]; CNTF, EC50 = 0.1 pM [18,42]); this may reflect differences
related to species, human stem cell origin or batch of neurotrophic
factor. Since the effects of neurotrophic factors on rat motor
Survival Factors for Human Motor Neurons
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Figure 3. Y-27632 enhances proliferation of motor neuron progenitors in hESC- and hiPSC-derived motor neuron cultures. (A) Y-
27632-supplemented cultures contain increased numbers of OLIG2-positive cells at day 31+9. Scale bar = 50 mM. (B) Time-dependent increase in
numbers of OLIG2-expressing progenitors in the presence of Y-27632. Data normalized to control at day 31+1; mean6 s.e.m., n.5 (t-test, **p,0.01).
(C) OLIG2 progenitors at day 31+9 stained for BrdU. Scale bar = 25 mM. (D) Percent of OLIG2 precursors that are BrdU-positive at day 31+9 (mean 6
s.e.m., n= 4). (E) Hb9::GFP-expressing motor neurons at day 31+9 stained for BrdU. Scale bar = 25 mM. (F) Percent motor neurons that are BrdU-
positive at day 31+9 (mean 6 s.e.m., n= 4). (G) The total number of cells in culture is increased at day 31+9 following Y-27632 treatment of hESC
Survival Factors for Human Motor Neurons
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neurons in defined media was reported to depend on intracellular
cAMP levels [40,41], we also tested the effects of inclusion of
forskolin and IBMX (F+I). The neurotrophic activity of each
factor tested appeared to be increased in the presence of F+I,
though this effect was only significant for single points at the
highest concentration of GDNF (Figure 5D-F). To determine
whether different neurotrophic factors were potentially acting on
different subsets of motor neurons in the cultures, we next
performed a dose-response analysis for a combination of all factors
with a fixed concentration of F+I (Figure 5H). The maximum
number of motor neurons maintained in culture was not
significantly greater than that with BDNF, CNTF or GDNF
alone (with F+I). This suggests that essentially all viable motor
neurons are maintained by optimal doses of these single factors, at
least after 7 days in culture. Therefore, like their rodent
counterparts, human motor neurons show an exquisitely sensitive
response to multiple neurotrophic factors.
Lastly, to evaluate the ability of the newly developed human
motor neuron survival assay to detect novel neurotrophic
compounds, we determined whether the beneficial effect of Y-
27632 on human motor neuron numbers, in addition to its effect
on progenitor proliferation, might also reflect a survival effect. To
exclude effects on cell attachment we first verified that the
presence of the drug did not affect hESC-MN numbers after
24 hours (Figure 6A). After 7 days in culture, Y-27632 had a clear
dose-dependent survival effect (Figures 6B and 6C), though to a
more modest extent than neurotrophic factors. The EC50 for the
Y-27632 survival effect on motor neurons was 2 mM, similar to the
value for motor neuron expansion. Thus Y-27632 not only
promotes proliferation of motor neuron progenitors but also
functions as a motor neuron survival factor. The fact that the fold-
increase in survival was lower than that induced in long-term
treatment of mixed cultures (Fig. 2B), likely reflects the absence of
proliferation and/or other cell types.
RUES1 and hiPSC18c. Values are mean6 s.e.m., n$3 (t-test, *p,0.05). (H) Numbers of OLIG2 precursors increase significantly at day 31+9 following Y-
27632 treatment of hiPSC 18c. Values are mean 6 s.e.m., n$3 (t-test, *p,0.05). (I) Numbers of motor neurons identified by staining for endogenous
HB9 increase significantly at day 31+9 following Y-27632 treatment of hESC RUES1 and hiPSC 18c. Values are mean6 s.e.m., n$3 (t-test, *p,0.05). (J)
Cultures from healthy control hESCs (RUES1) or hiPSCs (18c) immunostained for the motor neuron marker HB9 and the pan-neuronal marker b-III
tubulin. Y-27632 increases the number of motor neurons in each case. Scale bar = 25 mM.
doi:10.1371/journal.pone.0110324.g003
Figure 4. FACS-sorting of amplified cultures yields a pure preparation of viable human motor neurons. (A) Y-27632 supplementation
for 3 days leads to a 1.8-fold increase in motor neuron yield judged by FACS analysis. Data normalized to controls without Y-27632. Values are mean
6 s.e.m., n.5 (t-test, **p,0.01). (B) Nine-day treatment with Y-27632 gives a,5-fold increase in motor neuron yield as compared to controls without
Y-27632, as quantified by flow cytometry. Values are mean 6 s.e.m., n.5 (t-test, **p,0.01). (C) FACS purification of Hb9::GFP motor neurons
expanded with Y-27632 for 3 days. Representative FACS gating used to retrieve an almost pure (.95%) population of human motor neurons. (D)
FACS-purified motor neurons at day 31+3+1 stained for GFP (green), and a combination of HB9 and ISL1 (‘‘pan-MN’’; white nuclei). 95% of the FACS-
purified cells in culture are Hb9::GFP positive. Scale bar = 25 mM. (E) Even following FACS sorting, some contaminant cells were able to proliferate
and form colonies that interfered with survival assays (left panel). Uridine/Fluorodeoxyuridine (U/FdU) (each at 1 mM) successfully prevented the
proliferation (right panel).
doi:10.1371/journal.pone.0110324.g004
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Discussion
Human embryonic and induced pluripotent stem cells (hESCs
and hiPSCs) represent a powerful tool for studying human
development, disease modeling and drug discovery. However,
one major limiting factor for prospective drug screens is the
efficiency with which the affected cell types can be generated and,
in the case of motor neurons and many other neuronal classes, the
absence of a validated survival assay. Here, we took advantage of
our observation of ongoing motor neuron generation in hESC-
derived cultures to devise a new method for amplification of motor
neuron progenitors to increase motor neuron yields. In addition,
using optimized conditions for FACS sorting of neurons expressing
the Hb9::GFP reporter, we developed a robust assay for survival
factors acting directly on postmitotic motor neurons, and used it to
show that human motor neurons respond in a potent manner to
both known and novel neurotrophic molecules.
The ongoing neurogenesis in human motor neuron cultures that
we describe contrasts with the short ,24-hour period of motor
neuron production in differentiated mouse ES cell cultures [43].
This is likely to reflect normal biological differences in the
development of motor systems in rodent and human embryos,
since human motor neurons are produced over an extended three-
week period in vivo [28,29]. We first exploited this to screen for
compounds that would further amplify the precursor population,
identifying Y-27632 as the most active compound in a screen
which, like higher-throughput assays, was carried out at a single
concentration. Exactly how Y-27632 is achieving this may involve
multiple mechanisms, but we considered three potential modes of
action for Y-27632 in increasing numbers of motor neuron
progenitors. First, it could act by blocking differentiation of
progenitors to motor neurons. This seems unlikely since the
numbers of OLIG2-positive precursors and motor neurons
increased in parallel. Second, it might specifically promote the
generation of OLIG2-positive precursors. Since total DAPI
numbers increased in parallel, such a selective effect seems
unlikely. We therefore believe Y-27632 acts by shortening cell
cycle time for dividing precursors as a whole, leading to expansion
– but not enrichment – of motor neuron progenitors and a
subsequent increase in motor neuron yield [44–46].
Nevertheless, the ongoing neurogenesis also provides a poten-
tially serious confound for interpretation of experiments examining
changes in motor neuron numbers in mixed cultures. In studies
that do not take this into account, it is possible that an increase of
motor neuron numbers attributed to improved survival may
instead reflect an effect on neurogenesis. To overcome this issue,
we FACS-purified motor neurons derived from the Hb9::GFP
hESC line and cultured them alone in the presence of a mitotic
inhibitor U/FdU to inhibit proliferation of any remaining
progenitors. This is in some ways analogous to the approach
recently reported by Yang et al. [24], except that to block
proliferation they used cytosine arabinoside, which was cytotoxic
in our hands. Moreover, their cell survival experiments, performed
over a 20-day period, required a mouse astrocyte monolayer as
substrate, whereas our cultures contained essentially only motor
neurons.
Using this essentially pure preparation of postmitotic motor
neurons we showed that three known neurotrophic factors
potently enhance human motor neuron survival, and that their
action is potentiated when endogenous levels of cAMP are
Figure 5. Purified human motor neurons show a potent response to known neurotrophic factors. (A) Whole-well imaging of live motor
neurons labeled with calcein-AM captured using the Plate Runner (left two panels). Surviving human motor neurons were counted in whole culture
wells in an automated manner using MetaMorph (red tracing, right two panels). Scale bar = 200 mm. (B) Y-27632-expanded motor neurons show
enhanced survival in the presence of a cocktail of neurotrophic factors. Values shown as mean6 s.e.m., n.5 (t-test, ***p,0.001). (C) GDNF, (D) BDNF
and (E) CNTF alone (blue lines) enhance the survival of expanded FACS-purified human motor neurons. The addition of F+I significantly potentiates
the survival-inducing activity of GDNF at high concentrations. Values shown as mean6 s.e.m., n.4 (t-test, *p,0.05; **p,0.01; ***p,0.001). Asterisks
on individual points represent significance of difference with No-NTF control (white rectangle in the curve); asterisks on bars represent significant
differences between a given concentration of NTF and the corresponding value for NTF + F+ I. (F) The cocktail of neurotrophic factors (NTFs)
enhances the survival of expanded FACS-purified human motor neurons in a dose-dependent manner in the presence of 10 mM forskolin plus
100 mM IBMX. Values shown as mean 6 s.e.m., n$5 (t-test, **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0110324.g005
Figure 6. Y-27632 is also a survival factor for human motor neurons. (A) The plating efficiency of FACS-purified human motor neurons after
24 hours is not increased in the presence of Y-27632. (B) Y-27632 enhances the survival of FACS-purified human motor neurons in a 7-day survival
assay. Scale bar = 200 mM. (C) Dose-dependent effects of Y-27632 on human motor neuron survival, expressed relative to the basal condition (0 mM).
Values shown as mean 6 s.e.m., n$5 (t-test, *p,0.05; **p,0.01).
doi:10.1371/journal.pone.0110324.g006
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increased. Therefore, in this respect, the human stem cell-derived
neurons closely resemble rodent motor neurons both in primary
culture and in vivo. Since dependence on trophic factors is
acquired over time during embryogenesis [47], this also suggests
that the human motor neurons have reached a stage of maturation
comparable to those in the mid-embryonic period in mice.
Y-27632 has been shown to have contrasting biological effects
in different systems, ranging from pro-proliferative effects on
hESCs and hiPSCs [48,49] to anti-proliferative effects on cancer
cells [50], cord blood-derived CD34+ hematopoietic progenitor
cells [51], hepatic stellate cells [52] and smooth muscle cells [53].
While it is neuroprotective for primary mouse Purkinje cells [54],
retinal ganglion cells [55] and murine hippocampal slice cultures
[56] and growth-promoting for corticospinal tract axons [57,58]
and adult optic nerve [59], Y-27632 is not protective for hiPSC-
derived dopaminergic neurons [60]. Our study extends others
which suggest that Y-27632 exhibits generally beneficial effects on
motor neurons. A recent report documented an increase in the
lifespan of an intermediate mouse model of SMA following
administration of fasudil, another ROCK inhibitor [61]. Even
though the compound was not able to halt motor neuron loss in
the ventral horn of the spinal cord, positive effects on the
maturation of the neuromuscular junction and muscle fiber size
were reported [61]. More recently, fasudil was reported to extend
survival – and reduce motor neuron death - in a mouse model of
amyotrophic lateral sclerosis [62]. Therefore, the neurotrophic
properties of Y-27632 described here for cultured human neurons
likely reflect a mechanism of action that is conserved across species
and in vivo.
In summary, our study defines conditions for systematic assays
of neurotrophic factors and survival-promoting compounds for
human motor neurons. We show that the technique can be
extended to human iPSC-derived motor neurons and therefore in
principle to comparisons between cells derived from ALS patients
and controls: we and others recently derived Hb9::GFP or
Hb9::RFP reporters for different ALS-iPSC lines [63]. Important-
ly, in agreement with our earlier studies on the expression of
specific markers, electrophysiological characteristics and develop-
ment following transplantation [6,30], we show that the neuro-
trophic dependence of human stem cell-derived motor neurons
has reached a state of maturity comparable to that of primary
embryonic motor neurons in vitro and in vivo. Although more still
needs to be done before they can be considered to reflect the
properties of the postnatal spinal cord, this validates their use as a
human model for analyzing multiple aspects of motor neuron
development and pathology.
Materials and Methods
Cell lines
All the human ES and iPSC lines have been reported in an
earlier publication [6]. The iPS cell lines were derived by retroviral
transduction of OCT4, SOX2, and KLF4 in dermal fibroblasts.
All pluripotent cell lines were characterized by conventional
methods and grown under standardized conditions as described
below.
Ethics Statement
The work performed with human motor neurons derived from
hESCs and hiPSCs has been approved by Columbia University
ESCRO committee (Embryonic Stem Cell Research Oversight
committee). Patient fibroblasts for generating human iPS lines
were collected with written informed consent under IRB approval
AAAC1257 from Columbia University Medical Center.
Growth of hPSC lines
We used an HB9::GFP reporter hESC line [23], the wild-type
hESCs line RUES1 and hiPSC line 18c [6]. All cell cultures were
maintained in a humidified incubator at 37uC and 5% CO2.
Human ESCs and hiPSCs were grown on a pre-gelatinized tissue
culture flask on a monolayer of irradiated CF-1 mouse embryonic
fibroblasts (MEFs; GlobalStem) plated at 15,000–18,000 cells/cm2
in hPSC medium [DMEM/F12 (Invitrogen), 20% knockout
serum replacement (Invitrogen), 1 mM L-glutamine (Gibco),
100 mM non-essential aminoacids (Gibco) and 100 mM b-mer-
captoethanol (Sigma-Aldrich)] supplemented with 20 ng/ml
recombinant human basic fibroblast growth factor (bFGF; R&D
Systems). Medium was changed every day for the duration of the
expansion and lines were passaged every 4–6 days using dispase
(Gibco) at 1 mg/mL in hPSC medium for 30 minutes at 37uC.
Differentiation of hESCs and hiPSCs into motor neurons
hESCs and hiPSCs were allowed to reach 75%–90% con-
fluency. Then, colonies were treated with dispase (1 mg/mL) to
separate colonies from the MEF layer. After 30 minutes, cells were
washed off the flask using hPSC medium and collected in a 50 mL
Falcon tube. Colonies were allowed to settle by gravity and then
medium was aspirated. Fresh hPSC medium was added to the
cells. This step was repeated three times to wash away all the
remaining dispase. Settled colonies were then mechanically
dissociated into small 10- to 15-cell chunks using a P1000 tip by
performing up and down movements in a 1 mL volume. Cell
aggregates were transferred to low adherence T75 flasks in hPSC
medium with 20 ng/mL bFGF and 20 mM Y-27632 (Ascent) for
the first 24 hours. At day 1, cells for all experiments were
supplemented with hPSC medium containing 20 ng/mL bFGF,
20 mM Y-27632, 10 mM SB431542 (Sigma-Aldrich) and 0.2 mM
LDN193189 (Stemgent). The medium was changed daily from
day 2 to day 4. At day 5, embryoid bodies (EBs) were switched to
medium composed of 50% hPSC medium and 50% neural
induction medium [NIM; DMEM/F12 (Invitrogen), 1% N2
supplement (Invitrogen), 1 mM L-glutamine (Gibco), 100 mM
non-essential aminoacids (Gibco) and 2 mg/mL heparin (Sigma-
Aldrich)] supplemented with 10 mM SB431542, 0.2 mM
LDN193189, 10 ng/mL recombinant human brain-derived neu-
rotrophic factor (BDNF; R & D Systems), 0.4 mg/mL ascorbic
acid (Sigma-Aldrich) and 1 mM retinoic acid (Sigma-Aldrich). At
Day 7 cells were switched to 100% NIM, keeping the same
medium supplementation. Every other day between days 9 and 21,
NIM supplemented with 10 ng/mL BDNF, 0.4 mg/mL ascorbic
acid, 1 mM retinoic acid and 200 ng/mL recombinant C25II
modified sonic hedgehog protein (SHH; Invitrogen) was added to
the EBs. At day 22, cells were cultured with 50% NIM and 50%
neural differentiation medium [NDM; Neurobasal (Invitrogen),
1% N2 Supplement (Invitrogen), 1 mM L-Glutamine (Gibco) and
100 mM Non-Essential Aminoacids (Gibco)] supplemented with
2% B-27 supplement (Invitrogen), 0.4 mg/mL ascorbic acid, 1 mM
retinoic acid, 200 ng/mL SHH (Invitrogen), 10 ng/mL BDNF,
10 ng/mL recombinant human ciliary neurotrophic factor
(CNTF; R & D Systems), 10 ng/mL recombinant human glial
cell line-derived neurotrophic factor (GDNF; R & D Systems) and
10 ng/mL recombinant human insulin-like growth factor 1 (IGF-
1; R & D Systems). Between days 24 and 31, the bulk medium was
switched to 100% NDM and the EBs grown under the previous
medium supplementation. After 31 days of differentiation the EBs
were dissociated and the resulting neuronal cultures cryopre-
served. Briefly, the EBs were collected in a 50 mL Falcon tube and
then washed twice with PBS without Ca2+ and Mg2+ (Invitrogen)
to eliminate residual media. The EBs were then incubated at 37uC
Survival Factors for Human Motor Neurons
PLOS ONE | www.plosone.org 10 October 2014 | Volume 9 | Issue 10 | e110324
in pre-warmed 0.05% Trypsin-EDTA (Invitrogen) for 5–10
minutes. Lastly, fetal bovine serum (Invitrogen) supplemented
with 100 mg/mL deoxyribonuclease I (DNAse I, Sigma-Aldrich)
was added to stop the trypsin reaction and the cells were spun for 5
minutes at 4006g. The cells were resuspended in 1 mL of
complete trituration and wash medium [CTWM, PBS without
Ca2+ and Mg2+, 25 mM Glucose (Sigma-Aldrich), 4% L-15
dialyzed BSA (Sigma-Aldrich), 100 mg/mL DNAse I, 1% N2
supplement, 2% B27 supplement, 600 mM magnesium chloride
(Sigma-Aldrich), 500 nM EDTA (Sigma-Aldrich) and 2% FBS]
and subsequently mechanically triturated using a P1000 tip. The
resulting cell suspension was filtered using a 40 mM cell strainer
(BD Falcon) to eliminate large residual clumps and centrifuged for
5 minutes at 4006g. The cells were then resuspended in NDM
supplemented with 2% B27, 0.4 mg/mL ascorbic acid, 25 mM
glutamate E (Sigma-Aldrich), 25 mM b-mercaptoethanol (Milli-
pore), 0.1 mM retinoic acid, 10 ng/mL BDNF, 10 ng/mL CNTF,
10 ng/mL GDNF and 10 ng/mL IGF-1. These cells were
counted and then prepared for cryopreservation using 2x Freezing
Media (Millipore). Vials of 5–10 million cells/mL were prepared
to be used in further experiments.
Coating of 96-well plates
All survival and proliferation studies were performed in 96-well
plates (Greiner Bio-One) coated with polyornithine (Sigma-
Aldrich) and mouse laminin (Invitrogen). Briefly, 100 mg/mL
polyornithine (Sigma-Aldrich) in cell culture water was added to
the wells for at least 2 hours then aspirated and the wells rinsed
once using water. Coating was completed by adding overnight
15 mg/mL mouse laminin in L15 medium (Sigma-Aldrich)
supplemented with 7.5% sodium bicarbonate (Gibco). In studies
involving FACS-sorted cells, a concentration of 1000 mg/mL
polyornithine was used for coating.
Studies involving mixed hPSC-derived motor neuron
cultures
All proliferation/survival studies involving mixed hPSC-derived
motor neuron cultures were started from previously cryopreserved
vials. After quickly thawing the vials in a 37uC water bath, cells
were resuspended in NDM medium supplemented with 2% B27
Supplement. Cells were then spun at 4006g for 5 minutes. The
supernatant was gently aspirated and cells resuspended in 10 mL
of NDM with 2% B27. A 4% BSA protein cushion was then
layered under the cell suspension and the cells spun at 4006g for 5
minutes, with low acceleration and deceleration. Afterwards, cells
were resuspended in basal medium (BM) [Custom Clear
Neurobasal (Invitrogen), which omits phenol red and riboflavin
to allow live fluorescent imaging in the presence of a significantly
attenuated auto-fluorescent background; 1 mM L-glutamine and
100 mM non-essential aminoacids, 2% B27, 0.4 mg/mL ascorbic
acid, 25 mM glutamate E, 25 mM b-mercaptoethanol, 0.1 mM
retinoic acid] and counted using a hemocytometer. Finally, cells
were resuspended at the final desired seeding concentration of
32,000 cells/well and 100 mL was added to each well. Cells were
allowed to attach at 37uC for 2 hours before addition of
supplements at 3x concentration in 50 mL of BM.
Screening for small molecules with the potential to
increase numbers of human motor neurons in culture
From a collection of drug-like chemicals from the Microsource
and Tocris collections, two plates containing a total of 160
compounds were selected. Each compound was tested at 10 mM.
Basal medium to dilute compounds from original stocks was M-
199 (without phenol red; Invitrogen) with 5% DMSO (100%
anhydrous, Fisher Scientific), freshly prepared. Survival in BM was
used as negative control (trophic factor deprivation). Survival in
BM supplemented with a cocktail of NTFs [BDNF, CNTF,
GDNF and IGF-1] plus the cAMP-elevating compounds forskolin
(F; 10 mM; Sigma-Aldrich) and isobutylmethylxanthine (I;
100 mM; Sigma-Aldrich) was the positive control (trophic factor
supplementation). Cells were seeded at 32,000 cells/well in 150 mL
and compounds added in a 15 mL volume (the final DMSO
concentration of 0.45% did not adversely affect motor neuron
survival when added alone, not shown). The same volume of M-
199 with 5% DMSO was added to the negative control wells.
NTFs + F + I were also added in 15 mL of M-199 with 5% DMSO
in positive control wells. For each set, compounds were tested in
quadruplicate by creation of 4 test plates. In each plate, each
control condition (positive and negative) had six replicate wells.
Readouts were performed on day 31+13. After quantification of
the total number of surviving cells with significant neurite
outgrowth (see Results), data were plotted as mean fold difference
as compared to numbers in the negative control condition. Plates
were rejected when the mean difference in cells numbers between
positive and negative control was lower than 1.3 fold. Validation of
the most active compounds was performed by serial dose response
studies.
Immunocytochemistry
Neuronal cultures were pre-fixed by adding one volume of 4%
paraformaldehyde diluted in phosphate-buffered saline 1x
(PBS1x/4%PFA) for 2 minutes at room temperature. Then, cells
were fixed with PBS1x/4%PFA for 30 minutes at 4uC. After
fixation, cells were washed with PBS1x three times for 5 minutes
and then permeabilized and quenched for at least 30 minutes
using PBS1x with 0.1% Triton-X (PBSTX-0.1%) supplemented
with 100 mM glycine and 0.1% Sodium Azide (Sigma-Aldrich).
Cells were blocked in PBSTX-0.1% containing 10% donkey
serum (Sigma-Aldrich) and 0.1% sodium azide (Sigma-Aldrich)
(blocking solution) for one hour. After blocking, cells were
incubated overnight at 4uC with primary antibodies diluted in
the blocking solution. Primary antibodies used in this study were
the following: rabbit anti-GFP (1:3000, Abcam), mouse anti-ISL1
(1:200, DSHB, 39.4D5), guinea-pig anti-ISL1 (1:2000, courtesy of
Susan Brenner-Morton, Jessell laboratory at Columbia Universi-
ty), mouse anti-HB9 (1:100, DSHB, MNR2 81.5C10-c), chicken
anti-b-III Tubulin (TUJ1, 1:1000, Neuromics), rabbit anti-Olig2
(1:1000, Millipore) and rat anti-BrdU (1:150, Serotec). Cells were
washed five times with PBSTX-0.1% for 5 minutes. Antigens were
visualized by incubating for 60–75 minutes at room temperature
with the appropriate secondary antibodies (DyLight 488, 549 and
649 conjugated, 1:1000, Jackson ImmunoResearch). Lastly,
neuronal cultures were again washed five times with PBSTX-
0.1% for 5 minutes and incubated in a solution containing DAPI
(1:50000, Sigma-Aldrich) for 15 minutes. Cells were washed once
with PBSTX-0.1% and then imaged.
BrdU incorporation studies
5-bromo-2-deoxuridine (BrdU) incorporation studies were
performed to analyze cell proliferation. Neuronal cultures were
incubated with BrdU (2 mM; Sigma-Aldrich) for the full duration
of culture until fixation with PFA. The standard protocol for
immunochemistry described above was followed for other antigens
besides BrdU. Then, to detect BrdU incorporation, cells were
again pre-fixed for 2 minutes at room temperature and fixed with
PBS1x/4% PFA for 15 minutes at 4uC. They were then washed
with PBS1x three times for 5 minutes. Cells were then incubated
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with pre-warmed (37uC) 2 M HCl in distilled water for 10 minutes
at 37uC, light protected. Lastly, the HCl was aspirated and cells
were incubated in 0.15 M boric acid in distilled water for 2
minutes at room temperature. Cells were then washed three times
with PBS1x for 5 minutes and blocked for 1 hour using blocking
solution. Finally, cells were incubated overnight at 4uC with rat
anti-BrdU primary antibody (1:150, Serotec) in blocking solution.
In order to correct for any non-specific background staining, the
same procedures were performed on samples incubated or not
with BrdU.
FACS purification and motor neuron survival studies
HB9::GFP reporter hESC-derived motor neurons were grown
in polyornithine/laminin-coated T75 flasks prior to FACS
purification in order to maximize the amount of cells retrieved
after the procedure. After the expansion period, the medium was
aspirated and cells washed once with PBS without Ca2+ and Mg2+
to eliminate residual medium. The cells were then incubated at
37uC in pre-warmed 0.05% Trypsin-EDTA for 5 minutes. DNAse
I-supplemented FBS was used to stop the trypsin reaction. Cells
were collected and centrifuged for 5 minutes at 4006g. Cells were
resuspended in complete trituration and wash medium [CTWM,
PBS without Ca2+ and Mg2+, 25 mM Glucose (Sigma-Aldrich),
4% L-15 dialyzed BSA (Sigma-Aldrich), 100 mg/mL DNAse I, 1%
N2 supplement, 2% B27 supplement, 600 mM magnesium
chloride (Sigma-Aldrich), 500 nM EDTA (Sigma-Aldrich) and
2% FBS], filtered through a 40 mM Cell Strainer (BD Falcon) and
centrifuged for 5 minutes, at 4006g. The cells were then
resuspended in 750–800 mL of CTWM and transferred to a
sorting tube (BD Falcon). Cells were sorted based on GFP
expression using a BD FACS Aria II sorter (Becton Dickinson)
configured with a 100 mm ceramic nozzle and operating at 20 psi
for no longer than 30 minutes. Purified cells were collected in a
tube containing CTWM. After collection cells were spun for 5
minutes at 400xg and resuspended in Basal FACS Medium [Basal
Medium with Clear Custom Neurobasal, supplemented with
1 mM uridine/fluorodeoxyuridine (U/FdU; Sigma-Aldrich),
100 Units/mL Penicillin (Invitrogen), 100 mg/mL Streptomycin
(Invitrogen) and 100 mg/mL Normocyn (InvivoGen)]. After cells
were counted using a hemocytometer, they were resuspended at
the final seeding concentration of 2000 cells/well and added to the
wells in 100 mL. Medium supplements were added to the cells at
3x concentration in 50 mL of Basal FACS Medium after the cells
were allowed to incubate at 37uC for 2 hours in order to attach to
the bottom of the plate. Readouts were performed after 7 days.
Calcein live imaging
To facilitate the imaging of FACS-sorted GFP-positive cells, we
used the Calcein-AM Red-Orange (Invitrogen) vital dye at 2.5 mM
concentration. Briefly, cells were incubated with the dye for 5
minutes and then extraneous fluorescence was quenched using
5 mg/mL hemoglobin before image acquisition using the Plate
Runner (Trophos).
Image acquisition and quantitative image analysis
Image acquisition was performed using either a Carl Zeiss
Observer Z1 epi-fluorescence Microscope (Carl Zeiss Inc.;
acquisition of 12 images per well at 10x magnification) or the
whole well imaging device Plate Runner (Trophos). Automated
quantitative image analysis of fluorescent surviving hESC-MNs
and stained neuronal cultures was performed using the Meta-
Morph Software V7.6 (Molecular Devices). The Neurite Out-
growth application in the software was employed to quantify
fluorescent human motor neurons that have neurite outgrowth
above a certain threshold, reducing the number of false-positive
cells such as non-viable neurons included in the analysis.
Quantitative analysis of stained hPSC-derived human motor
neuron cultures was performed using the Multi-Wavelength Cell
Scoring application. For a specific marker, positive cells were
selectively identified as having clear signal intensity above local
background. Intensity thresholds were set blinded to sample
identity. In a given experiment the same parameters were used in
all images analyzed. Parameters were only minimally adjusted
across different experiments.
Statistical Analyses
All quantitative data were analyzed using IBM SPSS Statistics
19 (IBM SPSS). For each set of data a double statistical evaluation
was performed: A) for each condition/time point mean values
were compared using one-way ANOVA statistical evaluation
followed by Tukey HSD Post-hoc test; B) possible interactions
between time and condition were assessed using two-way ANOVA
statistical evaluation. In cases involving only one time point and a
two-group comparison, p value was determined using Student’s t-
test. Differences were considered to be significant when p,0.05.
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